New drugs beyond biologics in rheumatoid arthritis: the kinase inhibitors
Orally available small molecule compounds have recently been developed for the treatment of RA, and inhibitors of signalling cascades, specifically inhibitors of kinases, have reached advanced stages of clinical development. The p38 mitogen-activated protein kinase blockers have shown poor clinical...
Saved in:
Published in | Rheumatology (Oxford, England) Vol. 50; no. 9; pp. 1542 - 1550 |
---|---|
Main Authors | , , |
Format | Journal Article |
Language | English |
Published |
Oxford
Oxford University Press
01.09.2011
|
Subjects | |
Online Access | Get full text |
Cover
Loading…
Summary: | Orally available small molecule compounds have recently been developed for the treatment of RA, and inhibitors of signalling cascades, specifically inhibitors of kinases, have reached advanced stages of clinical development. The p38 mitogen-activated protein kinase blockers have shown poor clinical response despite encouraging preclinical data. In contrast, inhibitors of the non-receptor tyrosine kinases, spleen tyrosine kinase and janus kinase 3, have demonstrated a significant clinical efficacy together with an acceptable safety profile. We herein present a review on published preclinical and clinical data on these new drugs. |
---|---|
Bibliography: | ObjectType-Article-2 SourceType-Scholarly Journals-1 ObjectType-Feature-3 content type line 23 ObjectType-Review-1 |
ISSN: | 1462-0324 1462-0332 |
DOI: | 10.1093/rheumatology/ker192 |